You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
石藥集團(01093.HK):度恩西布膠囊上市申請獲國家藥監局受理
格隆匯 04-19 17:56

格隆匯4月19日丨石藥集團(01093.HK)發佈公吿,公司附屬公司石藥集團中奇製藥技術(石家莊)有限公司度恩西布膠囊(商品名:克必妥)的上市申請已獲中國國家藥品監督管理局受理,並獲附條件批准上市及優先審評資格。

克必妥按照化藥5.1類申報,用於治療既往至少經過兩綫治療的復發╱難治性濾泡性淋巴瘤成年患者。美國食品藥品監督管理局(FDA)已於2018年9月批准該品種上市,是首個獲批的PI3K-δ和PI3K-γ雙重抑制劑。集團擁有該產品在中國(包括香港、澳門和台灣地區)開發及商業化的獨家許可權。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account